drugset / Trial / NCT06714084
CNCMT：a Multi-center, Prospective, Single-arm Study
Enrolling by invitation
20 enrolled
Hubei Cancer Hospital
Akeso Pharmaceuticals, Inc. · collabYichang Central People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of Cadonilimab in neoadjuvant chemotherapy and maintenance therapy for high-risk advanced cervical cancer receiving concurrent chemoradiotherapy
Timeline
- Start
- 2024-10-08
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | — |